Ashford Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Ashford Capital Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-1,483	Closed	-$1.56M	–	108
2024 Q3	$1.56M	Sell	1,483 -89	-6%	-$99K	0.19%	70
2024 Q2	$1.65M	Hold	1,572	–	–	0.22%	66
2024 Q1	$1.51M	Sell	1,572 -58	-4%	-$55.2K	0.2%	64
2023 Q4	$1.43M	Buy	1,630 +909	+126%	+$749K	0.19%	68
2023 Q3	$593K	Hold	721	–	–	0.09%	76
2023 Q2	$518K	Hold	721	–	–	0.07%	72
2023 Q1	$592K	Hold	721	–	–	0.09%	71
2022 Q4	$520K	Hold	721	–	–	0.08%	73
2022 Q3	$497K	Sell	721 -135	-16%	-$85K	0.08%	79
2022 Q2	$506K	Hold	856	–	–	0.07%	78
2022 Q1	$598K	Hold	856	–	–	0.06%	85
2021 Q4	$541K	Sell	856 -122	-12%	-$75K	0.05%	87
2021 Q3	$592K	Hold	978	–	–	0.05%	87
2021 Q2	$546K	Hold	978	–	–	0.05%	91
2021 Q1	$463K	Sell	978 -1,506	-61%	-$733K	0.04%	90
2020 Q4	$1.2M	Sell	2,484 -506	-17%	-$273K	0.12%	70
2020 Q3	$1.67M	Buy	2,990 +426	+17%	+$258K	0.2%	55
2020 Q2	$1.6M	Buy	2,564 +1,534	+149%	+$871K	0.21%	57
2020 Q1	$503K	Buy	+1,030	New	+$425K	0.09%	72

Other funds holding REGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Ashford Capital Management's REGN Position: Q4 2024 in Review

Ashford Capital Management sold out of Regeneron Pharmaceuticals (REGN) in Q4 2024, closing a stake of 1,483 shares — an estimated $1.56M sold.

Ashford Capital Management first reported a position in REGN in Q1 2020 and held it in 19 quarters. The position peaked at $1.67M in Q3 2020. 1,321 funds tracked by Wall St. Rank hold REGN as of Q4 2024.

Ashford Capital Management reported no remaining Regeneron Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
Ashford Capital Management sold 1,483 Regeneron Pharmaceuticals shares in Q4 2024, an estimated $1.56M.
Ashford Capital Management first reported a position in Regeneron Pharmaceuticals in Q1 2020 and held it in 19 quarters.
Ashford Capital Management's Regeneron Pharmaceuticals position peaked at $1.67M in Q3 2020.
1,321 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2024.

Based on Ashford Capital Management's 13F filing for Q4 2024, filed 18 Feb 2025.